A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Trial ID or NCT#

NCT02283762

Status

recruiting iconRECRUITING

Purpose

To investigate if Riociguat is effective in the treatment of systemic sclerosis.

SEND MESSAGE

View on ClinicalTrials.gov